A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

被引：44
|
作者：
Badros, Ashraf Z. [1 ]
Kocoglu, Mehmet H. [1 ]
Ma, Ning [1 ]
Rapoport, Aaron P. [1 ]
Lederer, Emily [1 ]
Philip, Sunita [1 ]
Lesho, Patricia [1 ]
Dell, Cameron [1 ]
Hardy, Nancy M. [1 ]
Yared, Jean [1 ]
Goloubeva, Olga [1 ]
Singh, Zeba [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.506.506
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma
    Manasanch, Elisabet E.
    Lee, Hans C.
    Patel, Krina K.
    Weber, Donna M.
    Lee, Hun Ju
    Thomas, Sheeba K.
    Chen, Wendy
    Oriabure, Onyeka
    Badillo, Maria
    Graham, Vivian
    Lei, Feng
    McCarthy, Magda S.
    Orlowski, Robert Z.
    Wang, Michael
    BLOOD, 2017, 130
  • [22] Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)
    Usmani, Saad Z.
    Hansen, Emily
    Steward, Doug
    Waheed, Sarah
    Panozzo, Susan B.
    Petty, Nathan M.
    Atrash, Shebli
    Abdallah, Al-Ola
    Ahmad, Nisar
    Hoering, Antje
    Crowley, John
    Barlogie, Bart
    BLOOD, 2012, 120 (21)
  • [23] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    BLOOD, 2022, 140 : 4450 - 4451
  • [24] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
    Mark, Tomer M.
    Forsberg, Peter A.
    Rossi, Adriana C.
    Pearse, Roger N.
    Pekle, Karen A.
    Perry, Arthur
    Boyer, Angelique
    Tegnestam, Linda
    Jayabalan, David
    Coleman, Morton
    Niesvizky, Ruben
    BLOOD ADVANCES, 2019, 3 (04) : 603 - 611
  • [25] Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Kampfenkel, Tobias
    Liu, Weiping
    Kosh, Michele
    NamPhuong Tran
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2022, 140 : 7272 - 7274
  • [26] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
  • [27] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [28] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    BLOOD, 2016, 128 (22)
  • [29] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [30] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345